These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 8153471)

  • 1. [The mechanisms of action of etophylline-clofibrate in hyperlipidemia].
    Păduraru I; Nechifor M; Dănilă G; Jercă L; Filip M; Iacobovici A; Teslaru E; Filip C; Saramet A
    Rev Med Chir Soc Med Nat Iasi; 1993; 97(1):445-9. PubMed ID: 8153471
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lipid depression by etofibrate in a comparative study in rats with artificial hyperlipidemia].
    Sterner W; Schultz A
    Arzneimittelforschung; 1974 Dec; 24(12):1990-2. PubMed ID: 4480360
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapeutic of acetiromate on hyperlipidemia--comparison with clofibrate using a double-blind method].
    Nakano Y; Fukui I; Niiho S; Kuki H; Takahata J
    Nihon Rinsho; 1974 Jul; 32(7):2526-51. PubMed ID: 4612204
    [No Abstract]   [Full Text] [Related]  

  • 4. [Comparative evaluation of beta-benzalbutyramide and clofibrate in the short-term treatment of hyperlipidemic patients].
    Marini U; Bargiggia A; Riboli P
    Farmaco Prat; 1981 Dec; 36(12):532-41. PubMed ID: 7319020
    [No Abstract]   [Full Text] [Related]  

  • 5. The results of animal studies with ciprofibrate, a new orally effective hypolipidemic drug.
    Arnold A; McAuliff JP; Powers LG; Phillips DK; Beyler AL
    Atherosclerosis; 1979 Feb; 32(2):155-63. PubMed ID: 454514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-lowering and antioxidant activities of Jiang-Zhi-Ning in Traditional Chinese Medicine.
    Chen J; Zhao H; Yang Y; Liu B; Ni J; Wang W
    J Ethnopharmacol; 2011 Apr; 134(3):919-30. PubMed ID: 21316437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The efficacy of substances with antihypoxic action in experimental hyperlipidemia].
    Ryzhenkov VE; Remezova OV; Triufanov VF; Vasil'eva LE
    Eksp Klin Farmakol; 1992; 55(5):39-41. PubMed ID: 1305449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of several hypolipidemic agents related to clofibrate.
    Beaumont V; Buxtorf JC; Jacotot B; Beaumont JL
    Atherosclerosis; 1974; 20(2):141-53. PubMed ID: 4369878
    [No Abstract]   [Full Text] [Related]  

  • 9. [The action of a fibric acid derivative on lipid metabolism].
    Filip M; Păduraru I; Nechifor M; Dănilă GH; Popovici I; Filip FM; Poşircă F
    Rev Med Chir Soc Med Nat Iasi; 1989; 93(3):573-6. PubMed ID: 2636755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The treatment of essential hyperlipidemia with clofibrate].
    Reuter W; Seifert A
    Z Gesamte Inn Med; 1969 Jan; 24(1):Suppl:184-7. PubMed ID: 4918619
    [No Abstract]   [Full Text] [Related]  

  • 11. [Index of "unbound" thyroxine in patients with hypercholesterolemia or hypertriglyceridemia treated with clofibrate].
    Felt V; Strasek J; Bednár J
    Cas Lek Cesk; 1972 Sep; 111(40):929-31. PubMed ID: 4628030
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of pantethine on different models of experimental hyperlipidemia in rodents: a comparison with clofibrate.
    Farina R; Lovati MR; Raucci G; Sirtori CR
    Pharmacol Res Commun; 1982 Jun; 14(6):499-510. PubMed ID: 7122675
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hypolipemic activity of ITA 104].
    Vilageliu J; Zapatero MD; Bruseghini L
    Arch Farmacol Toxicol; 1978 Apr; 4(1):135-6. PubMed ID: 697379
    [No Abstract]   [Full Text] [Related]  

  • 14. [The importance of determining the type of hyperlipidemia for lipotropic therapy of atherosclerosis].
    Bavina MV; Perova NV; Lobova NM; Koropova GI
    Kardiologiia; 1973 Mar; 13(3):27-33. PubMed ID: 4717180
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical experimentation of clofibride. Apropos of 40 cases].
    Warembourg H; Jaillard J
    Lille Med; 1973 Dec; 18(10 Suppl 5):suppl 5:1292-6. PubMed ID: 4802928
    [No Abstract]   [Full Text] [Related]  

  • 16. [Use of symfibrate in the treatment of hyperlipemias. Preliminary data].
    Giuliani A; Trezzini C; Urbinati G; Conti R
    Clin Ter; 1979 Mar; 88(5):481-9. PubMed ID: 466970
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effects on the serum lipids of bis (hydroxy-2 ethylthio) 1,10 decane (LL 1558) and clofibrate, based on 91 cases of primary hyperlipoproteinemia].
    Rouffy J
    Sem Hop Ther; 1973 Jan; 49(1):31-6. PubMed ID: 4712022
    [No Abstract]   [Full Text] [Related]  

  • 18. The antilipemic effectiveness of aluminium clofibrate on hyperlipidemic patients with or without diabetes mellitus.
    Lam HC; Li SH; Wang JT; Tang KT; Ho LT
    Zhonghua Yi Xue Za Zhi (Taipei); 1987 Nov; 40(5):463-70. PubMed ID: 3332236
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hypolipidemic, hypocholesterolemic and antisclerotic action of the rotenoid glycoside amorphin].
    Kurmukov AG; Aĭzikov MI; Rasulova SA; Makhmudov OKh
    Farmakol Toksikol; 1986; 49(6):54-7. PubMed ID: 3817147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of hyperlipidemias. Value of a new hypolipidemic drug clofibride, (M-G. 46)].
    Leutenegger M; Choisy H; Caron J; Paris H
    Therapie; 1974; 29(4):599-610. PubMed ID: 4439371
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.